KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Sep 1, 2026
Kazia Therapeutics reported preclinical data showing its lead asset paxalisib reduced tumor burden by 52% (p=0.035) in MSS/pMMR colorectal cancer models, while adding paxalisib to immunotherapy cut tumor volume by an additional 50% versus immunotherapy alone. The company plans a five-arm Phase 2 trial of paxalisib alone and with pembrolizumab in pre-treated MSS/pMMR metastatic colorectal cancer, with enrollment expected to begin in Q1 2027 and full enrollment by end of 2027.
Key figures
- Phase2 crc arms
- 5 (paxalisib 15mg; 15mg + pembrolizumab +/- biologic; 30mg; 30mg + pembrolizumab +/- biologic; standard-of-care)
- Registered adss
- 10700211
- Crc full enrollment
- end of 2027
- Breast cancer full readout
- 2028
- Breast cancer first patient
- by end of 2026
- Crc phase2 enrollment start
- Q1 2027
- Breast cancer expansion arms
- 3 (paxalisib 15mg + fulvestrant + palbociclib; 30mg + fulvestrant + palbociclib; fulvestrant comparator)
- Ads last sale price 2026 08 31
- 13.77
- Ordinary shares underlying adss
- 5350105500
- Tumor burden reduction crc monotherapy
- 52% (p=0.035)
- Expected new us breast cancer cases 2026
- nearly 322,000
- Hr her2 share of breast cancer diagnoses
- 60-70%
- Mss pmmr share of metastatic colorectal cancer
- 85-90%
- Additional tumor volume reduction with immunotherapy combo
- 50% (p=0.022)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.